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The AIDS Project
Will Participate
in the Southern Maine
Pride Parade
to Celebrate
the G/UB/T Community.
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by David Aaron Swander
On Saturday, June 19, 1999, The AIDS Project will be participating in the Southern Maine Pride Parade in Portland. Our focus
will be to "thank" the community and the volunteers for all their
support over the years. The parade will begin at noon in
Monument Square, heading up Congress Street, down High
Street and ending in Deering Oaks Park. Those wishing to march
with TAP employees, board members, and volunteers are encouraged to call TAP for more information. (Ask for David Aaron or
Daniel when you call TAP at774-6877.)
We are in the process of finding t-shirts for the parade volunteers and need a tally of how many TAP marchers to expect.
Vehicles may be arranged for those who cannot walk the parade
route. We hope you can join us!

TAP Office Closed May 20th
The AIDS Project's office in Portland will be closed on
Thursday, May 20th for painting. We will resume normal
business hours the next day.
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by the way
by Mike Martin
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back to school special
Going back to school was a lot more fun than I had
expected it to be. The AIDS Project was recently invited to do
some HIV prevention education at South Portland High
School. So Gloria Leach, TAP's Community Educator;
Declan Buckley, TAP's Outreach Worker; Doug Eaton,
TAP's Hotline and Counseling and Testing Coordinator; and
I headed out to South Portland High where we spoke to the
four classes individually (freshman, sophomores, juniors,
and seniors) in their very impressive auditorium. Each class
has about 200 students.
This was the first time I had been asked to speak with
the folks from TAP's Prevention Education department.
Mostly I have spoken to healthcare students and professionals, from Biddeford to Orono, in conjunction with the AIDS
Consultation Service of Maine Medical Center. So, not only
was I facing a new audience, but a new cast as well. I am
pleased to say that we hit it off all around.
As the kids straggled into the auditorium, some of
them horsing around, some of them looking decidedly wary, I
noticed some of them were wearing red ribbons, in support of
AIDS awareness. Then the principal introduced us and
Gloria led the way. Gloria is 65 years old and so she began her
talk by saying, "A lot of you are probably wondering why
your grandmother is talking to you about HIV!" It's a great
icebreaker, and the kids all laughed.
And then for an hour and fifteen, with each class,
Gloria, Declan, Doug and I talked to the kids about HIV and
AIDS. The school allowed us to be very frank with the kids,
and the kids really paid attention. The invitation to speak
came about because students and teachers at the school let the
principal know that they wanted to go further in their HIV
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education than what they were learning in health classes. We
certainly went further. Gloria has a very straight-forward
approach to HIV education and she set the tone for these
sessions.
Of course, the hope is that by reaching over 800 kids,
we will make a dent in the epidemic of HIV. Studies indicate
that young, gay men are slacking off when it comes to safer
sex. And, in youth in general, there is a growing complacency about safer sex practices, though, by the curiosity and
attention, we received at South Portland High, you wouldn't
know it. These kids seemed very aware and eager to know
more.
After each session, the kids were invited to come up
to us and ask questions if they had any. Mostly the kids who
came up to me just wanted to tell me about a relative of their's
who had HIV, or had died of AIDS and for whom they had
made a quilt panel.
In a time when Maine high schools are feeling the
effects of the shootings and bombings at Columbine High in
Colorado, being safe is on kids' and teachers' minds. The
principal even said in her introductions that the reason for
having The AIDS Project come to the school was all about
helping the kids be safe and healthy.
The greatest challenge in the epidemic is to reach out
to youth with information and real stories about HIV and
AIDS, to help them make responsible decisions about their
sexual practices. I was very impressed with Gloria, Declan,
and Doug, and with the students and staff at South Portland
High. And I can't help but think that the message got through
to a lot of those very attentive students. The message being
that information is power -- power to stay healthy. •

IN THE AFFIRMATIVE
In The Affirmative is a monthly newsletter published by The AIDS Project for people
living with and affected by HIV/AIDS. Letters, articles, or other submissions should be
sent to: In The Affirmative, c/o The AIDS Project, P.O. Box 5305, Portland, ME 04101, or
call (207) 774-6877. Submissions can be printed anonymously as long as the person
submitting the material includes his or her name and phone number for verification.
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A Safe, Healthy, and Friendly
Meeting Place for
HIV-positive People
in Southern Maine.
by Billy, Johnathan, and Judy

The Wellness & You Program
at the University Of New England,
Westbrook Campus.
When people hear the name of this program, images of kindergarten field trips and basket weaving may come to
mind, but Wellness & You, sponsored by the University Of New England and the AIDS Project, is anything but a
walk in the park. This nationally-recognized program for people living with mv offers many unique opportunities.
Working out has been proven to help bolster the immune system. Statistics show that maintaining healthy
muscle mass will increase an individual's quality oflife. This is a program about individualized health care for those
living with HIV. It can include everything from stretching exercises to free weights, cardiovascular training to HIVrelated nutritional information, as well as introductions to alternative therapies such as yoga, massage, Tai Chi,
Reiki, and self-defense .
Wellness & You provides a safe meeting place. The participants are all people living with HIV. Attending
provides the opportunity for HIV-positive people to help each other combat the isolation of being positive in the
state ofMaine. Men and woman, straight and gay are all together sharing their growth through healthy channels.
A special thanks to the University OfNew England for providing such a safe and comfortable atmosphere. Also,
thanks to Judy Vezina, the program's coordinator, for contributing to this well-supervised experience.
Some participants have commented that, "the Wellness program and Judy saved my life," and "it's one of the
best experiences I have had in the state of Maine. "For better health and as an alternative meeting place with a safe
and comfortable environment, the Wellness & You program can't be beat!

Wellness & You is currently accepting new members, for more information, please contact: Daniel Schnorbus, TAP's Client Services Coordinator, at The AIDS Project in Portland
at 774-6877 or Denise Ferer, TAP's York County Case Manager at The AIDS Project in
Kennebunk at 985-8199. •

Wellness Participants' Photos.
(Top) Ron Goben does some crunches.
(Bottom, Left to Right) Ron rides the stationary bike. Neal Brown is
checked out by Wellness Coordinator Judy Vezina. Neal works with some
of the equipment available at UNE.
·
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Lipidostrophy: Glaxo Researchers Suggest
Mechanisms, Publish Data
AIDS Treatment News (03/19/99)

Abnormal Body-Fat Distribution in HIV-1-lnfected
Children on Antiretrovirals
Lancet (04/ 10/99)

AIDS Lifts Danger of Cancers
Sydney Morning Herald Online (05/01/99)

At the recent conference of retroviruses in Chicago,
researchers from Glaxo Wellcome presented hypotheses
and related data on lipodystrophy in HIV-infected patients,
which many scientists believe is associated with protease
inhibitor therapy. Some patients have shown high
cholesterol and triglyceride levels, abnormal fat deposits,
and the development of insulin resistance. Studies show
that saquinavir, ritonavir, and nelfinavir greatly reduce the
development of fat cells from stem cells in vitro. The drugs
also increased the metabolic destruction of fat in existing
fat cells. The loss of deposited fat in the body could lead to
high levels of low-density lipoprotein cholesterol and
triglycerides. Another proposed mechanism involves
retinoids, compounds that are related to vitamin A. When
protease inhibitors and retinoids were combined, complex
reactions were observed in certain genes. lndinavir may
cause some effects resembling lipodystrophy by changing
retinoid signaling. If the mechanism is correct, patients
receiving indinavir may be at risk if they also take vitamin A
supplements.

Researchers from the Boston University School of
Medicine investigated the prevalence of abnormal bodyfat distribution in HIV-I -infected children. The authors
based their data on a survey sent to all pediatric AIDS
Clinical Trial Groups and National Institute of Child Health
and Human Development sites between March and
August of last year. Of the 55 sites responding, 16
reported at least one instance of abnormal fat distribution.
A total of 1,644 out of 2, 713 children on antiretroviral
therapy were taking protease inhibitors. One percent
experienced abnormal fat distribution; 0.4 percent of
those who did were not taking protease inhibitors, while
1.5 percent were taking the drugs. Nearly two-thirds of
the children with abnormal body fat were female, more
than 40 percent were African-American, and the average
age was 10.9 years. At the time of reporting, the mean
viral load in children with abnormal body fat was 98,000
copies, and the mean CD4-cell count was 367 cells. The
researchers note that future research should present a
standardized definition of abnormal body fat distribution, a
comparative analysis of risk factors, evaluations of
endocrine abnormalities, and correlations with particular
therapies.

Liposuction for Protease-Inhibitor-Associated
Lipodystrophy
Lancet (04/10/99)

Mexican researchers presented the case of a 46year-old man who used liposuction to treat the
lipodystrophy that developed as a result of his use of
saquinavir and nelfinavir. The man, who was diagnosed
with HIV in 1989, had been taking a combination of
zidovudine, zalcitabine, and saquinavir for about a year
when he observed a continued thickening of his neck. The
cocktail was switched to nevirapine, nelfinavir, and
didanosine, but more than a year later he developed a
buffalo hump as a result of abnormal fat accumulation in the
area. Until something else is developed, the researchers
note that liposuction may be an acceptable treatment for
abnormal fat deposits, which may play a role in noncompliance with antiretroviral regimens.

The AIDS Project
615 Congress Street· 6th Floor
(or 142 High Street)
P.O. Box5305
Portland, Maine 04101
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Fax: 985-8646 *51
E-mail: tap2@mail .javanet.com
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Declan Buckley,
MSM Outreach Worker
Diana Carrigan,
Cumberland County Case Manager
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HIV-2 Infection Not Protective Against HIV-1 Infection
Reuters (04/21/99)

New research suggests that infection with HIV-2
does not prevent HIV-1 infection. Because the two strains
have a similar transmission route, it had been thought that
immune response to HIV-2 would prevent subsequent HIV1 infection. However, a study in the April 16 issue of AIDS
found that women seropositive for HIV-2 were more likely
to generate evidence of infection with HIV-1 than women
seronegative for HIV, although the difference between the
groups was not statistically significant. In a second study
in the same journal, Dr. Hans Norrgren of the University
Hospital in Lund, Sweden, found that HIV-2-positive
individuals tended toward a higher risk of acquiring HIV-1
than their seronegative counterparts.

Janine Collins,
Cumberland County Case Manager
John Cronin,
MSM Outreach Worker
Carolyn Curtis,
Case Management Intern
Sequoia Dance,
Street Outreach Worker
Douglas Eaton,
Program Coard. of HIV Prevention
Denise Ferer,
York County Case Mngmt. Intern
Jill Frame,
HAVEN Case Manager
George W. Friou,
Executive Director
Demetra Giatas,
Development Director
John Green,
HIV Case Manager
John Holverson,
Director of Prevention and Education
Gloria Leach,
Community HIV Prevention Educator

New findings published in the journal AIDS indicate
that people with AIDS are more at risk of contracting
aggressive cancers. According to Dr. Andrew Grulich,
primary author of the study, AIDS patients are more likely to
get cancer of the skin or lip, as well as Hodgkin's Disease.
The study examined all cases of cancer until 1996 among
people diagnosed with AIDS between 1980 and 1993 in
New South Wales. The researchers noted that among more
than 3,600 AIDS diagnoses, there were 873 cases of
cancer, including 62 not usually linked to AIDS.
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Steroids Found to Help Patients Build Muscle
New York Times (04/14/99)

Two anabolic steroids provided renewed strength to
patients weakened from kidney dialysis and from weight
loss due to HIV infection, according to two separate studies
in an issue of the Journal of the American Medical
Association.
While more information is needed about dosage and
duration oftreatment, dialysis patients given steroids made
with nandrolone decanoate increased their average nonfat
body weight by 5.5 pounds more than the placebo
recipients, according to University of California at San
Francisco assistant professor Dr. Kirsten L. Johansen. The
second study, led by UCSF researcher Dr. Alison Strawford,
found that of 22 HIV-infected patients put on a modest
resistance weight lifting program, the 11 who received the
synthetic steroid oxandrolone gained an average of 16
pounds versus eight pounds for the placebo group. The
researchers observed, however, a significant decline in
high-density lipoprotein cholesterol in the steroid
recipients.

For more information, try checking out ti

www.thebody.com
www.hivpositive.com
www.projinf.org
www.aidsproject.org
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Researchers Discover AIDS Cocktail Can Rebuild
Immune System
Minneapolis Star Tribune Online (05/07/99)

HAART Failure Is Common in Clinical Practice
Reuters (04/19/99)

Dr. Zhi-Qiang Zhang and Dr. Ashley Hasse, both
researchers at the University of Minnesota, have found that
highly active antiretroviral therapy (HAART) may help the
immune system regenerate itself. The study, published in
Proceedings of the National Academy of Sciences, details
how Zhang and Hasse tracked the regeneration of the
follicular dendritic cell (FDC) network. The FDC network, a
key part of the immune system, is often targeted and wiped
out by HIV. Previously, researchers thought that once the
FDC network disappeared, it was gone for good; however,
the new findings indicate that the protective cells of
patients on HAART increased in number, approaching levels
of HIV-negative individuals. Study co-author Dr. Tim
Schacker cautioned, however, that the study involved only
individuals who responded well to HAART.
lmmunex Says Leukine Extends AIDS Therapy
Reuters (05/04/99)
The cancer drug Leukine is useful in helping to extend
AIDS patients use of antiretroviral drug cocktails, according
to the drug's maker, lmmunex. Data from the stage Ill study
indicated Leukine stimulates the immune system,
suppresses the virus, and lowers the incidence of all
infections and death. Unlike antiretroviral drugs that directly
attack the virus that causes AIDS, Leukine prevents HIV
from entering uninfected cells, as well as rejuvenating cells
weakened by the disease's progression. lmmunex noted
that 83 percent of the 57 patients in the study with
undetectable viral levels maintained that undetectable level
after 24 weeks of Leukine therapy, versus 54 percent of
patients who were given placebo.

these websites.
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San Francisco researchers report that in clinical
practice, many HIV patients who receive highly active
antiretroviral therapy with a protease inhibitor will
encounter virologic failure within one year. However, the
researchers, from San Francisco General Hospital and the
University of California, note that cases of immunologic
failure were rare during at least the first 12 months. The
study involved 337 patients, who all received at least 16
continuous weeks of HAART, and revealed that about half
the patients had plasma HIV RNA loads under 500 copies
after 48 weeks. The findings were published in the April 16
issue of AIDS.

TAP's York County
Clients Can Access
The Internet
York County Clients of TAP can
use the computer at its
Kennebunk office to access the
internet. Call Denise Ferer at
985-8199 to set up a time to
use the computer.
Also, clients can now e-mail
TAP's Kennebunk office at:
www.tap2@mail.javanet.com
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Why AIDS?
Science News (03/27/99)
Despite millions of dollars tor research
over the past 15 years that has produced many
powerful treatments tor AIDS, scientists have
yet to unravel the mystery of how HIV invades
the immune system and causes it to cease
functioning properly. While many scientists
initially believed that HIV attacked the immune
system by directly targeting helper T cells,
immune cells also known as CD4 cells, and
eliminating them, several new studies suggest
HIV uses a different mechanism to disrupt CD4
cells that is more important and may provide
more insight about potential treatments or
vaccines. Developed in 1995, one of the first
successful theories suggested that HIV
destroys CD4 cells, which forces th~ immune
system to produce more CD4 cells that then
support the spread of the virus rather than
protect against it. Researchers believed the
immune system would eventually run out of
steam and stop producing CD4 cells. However,
a study published in January's Nature Medicine
indicated that antiretroviral therapy was
responsible tor an increase in the production of
CD4 cells above normal levels, confirming that
HIV's impact on CD4 production was as
important as its impact on CD4 destruction. A
more recent theory reported in January's
Journal of Immunology showed the virus may
force many CD4 cells to leave the blood and
enter certain tissues and lymph nodes where
they are destroyed or self-destruct. The theory
was confirmed in mice but still needs to be
tested in humans.

Source for some of the information in this
newsletter include:
CDC HIV/STD/TB Prevention News Update
Contributors include:
Doug Eaton
Denise Ferer
Billy Hills
Karla McGowan
Daniel Schnorbus
David Aaron Swander
Judy Vezina
Johnathan Williams
People Art © David Cedrone
Kerry S. Tardiff, Distribution
Mike Martin, Editor
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HIV News
Risky Business
Advocate (04/13/99)
Experts are unable to explain why, and few if any can
understand the reasons when provided, but a number of
recent studies indicate there has been an increase in the
number of gay men who regularly engage in unprotected
anal sex, also known as barebacking. According to a survey
by the Centers for Disease Control and Prevention about gay
male sexual habits in San Francisco, 60.8 percent of men
surveyed in 1997 said they always used a condom,
compared to 69.9 percent in 1994. And 68 percent of those
who participated in unprotected anal sex with multiple
partners said they did not know the HIV status of all their
partners. For many gay men, the primary justification for
engaging in such risky behavior is that they do not see HIV
infection as a threat to their lives-a contention the scientific
community says is absolutely baseless.
Some experts investigating this potentially deadly
decision also note barebacking is seen by some as a way to
celebrate risk, while others point out that young gay men
living today automatically link being gay with having AIDS.
In younger populations, the problem is exacerbated by the
fact that many do not know a person who has died from
AIDS. The issue of barebacking is particularly difficult to
deal with for those trying to prevent HIV transmission and
who fear the trend spread could convince others it is okay to
have unprotected sex.

Teen-Agers Can Curb AIDS With Knowledge
Sun Herald Online (04/19/99)
Half of the new HIV cases in the United States involve
people under the age of 25. The causes for this have been
attributed, in part, to a lack of awareness and risky behavior.
Also, teenagers are having sex earlier than before, with 77
percent of girls and 86 percent of boys having had sex by
age 20. The three main routes to HIV infection are sexual
intercourse, intravenous drug use, and blood transfusions,
although blood testing has made this very rare. In
Mississippi, the group Pioneers for AIDS Counseling and
Training (PACTI encourages HIV education by sending
teenagers to speak about the issue to youth groups and
clubs. "We show videos and talk about some things that
make people uncomfortable, but it's so important," notes
PACT founding member, 16-year-old Natalie Davidson.

HIV News

HIV Drug News

A New Foe in the Fight Against AIDS
Boston Globe Online (04/21/99)

Supervised Breaks From HIV Meds May Strengthen
Immunity
MSNBC Online (05/04/99)

In a commentary, Larry Kessler, of the AIDS Action
Committee in Boston, cites a new attitude of complacency as the greatest hurdle facing those battling AIDS.
This complacency can be seen in reduced AIDS funding
and risky sexual practices. To fight the complacency,
Kessler points out that efforts should be redoubled in the
areas of prevention and in keeping HIV-infected individuals
healthy. He also suggests that clean needle programs and
education programs must be emphasized if the spread of
the disease isto be curbed.

Doctors Must Report Names of Those Who Test HIVPositive
Topeka Capital-Journal Online (04/16/99)

HIV Heresy
Kansas Gov. Bill Graves signed into law a measure
that would force physicians and laboratories to report to
the state Department of Health and Environment the
names and addresses of individuals testing positive for
HIV. Previously, only those diagnosed with AIDS had their
names reported to the state; cases of HIV were reported
only in terms of the number of infections. Under the new
bill, the secretary of the state health department would be
required to establish rules regarding the confidentiality of
data about HIV-infected individuals that are as demanding
as those employed by the Centers for Disease Control and
Prevention.

Ministers Seek to Cut AIDS Toll Among Blacks
Los Angeles Times Online (04/22/99)
A coalition of ministers will be working with the
state of California in an effort to fight AIDS in the AfricanAmerican community. In the United States, AIDS is the
No. 1 killer of African Americans between the ages of 25
and 44. The new Statewide Church Advisory Board will
provide materials, provide technical help, and a ministry
kit designed to teach religious leaders about the illness
and how to incorporate it into their sermons. The hope of
the ministers is that they will be able to disseminate
knowledge of the disease to their congregation, and so
help to cut incidence of the disease.

UK Sees Record HIV Infection Levels in 1998
San Jose Mercury News Online (04/13/99)

Checking in With David Ho
Rolling Stone (04/29/99)
In an interview with Rolling Stone, renowned AIDS
researcher Dr. David Ho discussed the state of the AIDS
epidemic. Participants at the International AIDS Conference
in Geneva last summer heard reports that the costly
combination drug therapy made famous by Ho does not
work for everyone, has stopped working in some, or has
significant side effects. But Ho points to the significant
decreases in AIDS-related deaths in the United States and
Europe in the past several years as evidence of progress.
He views a cure as a long-term goal, but sees the possibility
of the immune system being able to control the virus
without drugs as potentially much closer. Ho sees HIV
education and the development of a vaccine as two key
prevention measures. The researcher noted that AIDS
needs to become a national priority, citing the soaring rates
of infection in countries like South Africa, India, and China
as an example.

Investigators, fearing that the new antiviral
medications may be a temporary fix, are exploring the idea
of killing HIV with the body's natural defenses. Some
researchers also believe that genetic engineering may help
the body fight HIV. "One way to do that is to try to take the
cells that the patients have and now refocus them so they
can do what the virus has destroyed." John Ceravsky, an
American patient diagnosed with HIV, stopped taking his
medication at the recommendation of his doctors last
February. Although he has had to return to his medications
because the virus drove his T-cell count down, doctors note
that he can go longer and longer without medication.

New statistics estimate that the number of new HIV
infections in the United Kingdom rose to almost 3,000 last
year, the highest rate since the epidemic began. The
Terrence Higgins Trust, which made the predictions, said
the findings reflect a need for greater safe sex education.
The charity has yet to compile the final statistics for 1998,
but noted that the number of HIV-infected individuals in
the United Kingdom could increase by 50 percent to about
27,000 by 2003. A MORI poll on attitudes toward sex
revealed that many groups were still unaware of the risks
of unprotected intercourse, the trust said.

New Scientist (03/27/99)
While the use of so called drug cocktails has greatly
improved the lives of many HIV-infected patients, some
AIDS researchers now are proposing that patients take
carefully scheduled "holidays" from their combination
therapies to let the body's own immune system fight the
disease. Researchers advocating this approach believe that
suspending use of the drug cocktail, which interrupts two
key viral enzymes, will allow the body to create a strong
cytotoxic T lymphocyte (CTLI response that will control the
virus.
At the recent Conference on Retroviruses and
Opportunistic Infections, Franco Lori of the Research
Institute for Genetic and Human Therapy presented the
case of a patient in Bertin using a triple-drug combination
that was stopped twice and ultimately suspended who
showed negligible HIV levels after two years. A study by
Lori involving monkeys found a similar result at 145 days
after the animals had taken several monitored drug
holidays. Despite the animal study and other anecdotal
evidence of similar success, researchers emphasized that
randomized controlled trials were needed to be sure the
approach was effective in humans and did not lead to drug
resistance. If the strategy does prove effective, researchers
said it may be possible for some patients to suspend drug
treatment indefinitely.

Successful Treatment of Pediatric HIV-Related CMV
Encephalitis Reported
Reuters Health Information Services (04/16/99)
Swiss researchers report that combining ganciclovir
treatment with highly active antiretroviral therapy can
resolve the cerebral lesions and clinical symptoms of
pediatric HIV-related cytomegalovirus encephalitis. Until
now, only one case of successful treatment of pediatric HIVrelated CMV encephalitis has been reported; however, Dr.
Christoph Rudin, of the University Children's Hospital in
Basel. and colleagues detail in April's Pediatric Infectious
Disease Journal the second successful treatment of the
disease. The researchers found that within weeks of
receiving the new treatment, the subject's clinical and
neurological symptoms improved remarkably. According to
the researchers, the effectiveness of the treatment seems
to rest on its interdisciplinary approach, which utilizes
social and psychiatric support in addition to the prescribed
medical treatment.
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AIDS Hotline is Seeking Volunteers
Doug Eaton, Hotline Coordinator, is seeking applications
from qualified volunteers to fill vacancies on the Hotline. Doug
feels that using clients as Hotline workers would enhance the
service that the Hotline provides to those wanting information
about transmission, safer sex, and referrals to testing sites.
If you would like to talk with Doug about this opportunity,
give him a call at 775-1267 or 1-800-851-2437. If you get the
answering machine, please leave a message and Doug will get
back to you.
HIV and Women

HIV Vaccine News

HIV Drug News

Antiretroviral Therapy Reduces HIV Levels in Female
Genital Tract
Reuters (04/09/99)

Single-Strain Vaccine Danger
Scientific American (04/99)

Study AIDS Drugs Long-Term, Makers Told
Toronto Globe & Mail (05/04/99)

Single-strain vaccines may increase an individual's
risk of contracting disease, according to a new model
described in the January issue of Proceedings of the
National Academy of Sciences. Viruses often exist in
multiple strain complexes; antibodies to a single strain of a
virus are usually active against related strains.
Researchers found, though, that certain viruses react to
antibodies of closely related strains by mounting a more
severe attack on the host. In this scenario, vaccines
against single strains--such as some that are under
development against HIV--could result in increased risk of
disease.

Dr. Julio Montaner, co-director of the Canadian HIV
Trials Network, and treatment pioneer Dr. Jeep Lange,
recently criticized the pharmaceutical industry for
neglecting to study the long term side-effects of AIDS
drugs. Dr. Montaner said that pharmaceutical companies
should be required to do follow-up tests of their medication
as part of the approval process for the drugs. Increasingly,
some patients who have been using the powerful new AIDS
therapies have developed premature heart disease,
lipodystrophy, and liver disease. "What we have is a
tremendous improvement over what we used to have," Dr.
Lange said, "but we must find ways to reduce lifethreatening toxicity."

Correlations between plasma HIV levels and HIV
vaginal load have been reported, by researchers from the
CDC, along with major reductions in both after antiretrovial
therapy. The researchers say that successful antiretroviral
therapy may reduce ''the risk of perinatal and heterosexual
transmission by lowering vaginal virus load." The group
used a quantitative-competitive reverse-transcriptase
polymerase chain reaction assay to assess the correlation
between plasma and genital tract HIV levels.
Increased STD Risk Seen in HIV-Infected Women
Reuters (04/13/99)
Research published in the March issue of Sexually
Transmitted Diseases indicates that HIV-infected females
have a higher rate of lower genital tract infection. The study,
conducted by the Women's lnteragency HIV Study, also
revealed that sexually transmitted disease symptoms
become more noticeable over the course of HIV infection.
According to the authors, HIV-infected women were more
likely than HIV-negative women to have a history of STD's,
excluding bacterial vaginosis and chlamydia. To reduce the
occurrence of lower genital tract symptoms and possible
sequelae of STDs, the researchers recommend that women
infected with HIV receive careful gynecologic exams.
HIV-Infected Mother Loses Fight for Baby
Los Angeles Times (04/21/99)
On Tuesday, Juvenile Court Judge Maurice Merten
refused to give up state custody of an infant born to an HIVpositive woman who wants to breast feed. "The parents
may choose to run that risk with the child, but the court may
second-guess that decision," Judge Merten said. The fourmonth-old boy will be allowed to live with his family, but a
caseworker from Oregon's Office for Services to Children
will visit periodically to ensure that the order is being
fulfilled. Kathleen Tyson's case rested on the contention that
HIV does not cause AIDS and cannot be transmitted through
breast milk; however, witnesses for the state testified that
breast milk from an infected mother has a very high risk of
virus transmission.

After 17 Healthy Years, Hope of 'Safe' H.I.V. Dies
New York Times (04/20/99)
Australian researchers, studying a small group of
individuals who have been infected with HIV for years
without any AIDS symptoms, recently ended their hope of
developing a vaccine from the naturally weakened live
virus strain. The patients, who contracted HIV via
transfusions from one blood donor, have lived with HIV for
up to 17 years. However, the donor was diagnosed in
February with an AIDS-related infection of the brain and
spinal cord, and two patients have weakened immune
systems, although they have not become sick. The strain
of HIV was weakened by a natural deletion of net. The
researchers will continue to study the three infected
individuals who are still healthy.

Drugs May Cause AIDS to Lurk in Cells
Washington Post (04/27/99)
New research in the journal Nature Medicine
estimates that HIV can hide undetected in people taking
antiviral drugs for up to six decades. The drugs can reduce
the body's levels of HIV to undetectable levels, but they
cannot eliminate the hidden reservoirs of HIV in cells. The
researchers, led by Robert Siliciano of Johns Hopkins
School of Medicine, studied 34 HIV-infected adults who
were all taking virus-suppressing treatment. Based on
samples of "resting" CD4 T cells in the patients' blood, the
researchers estimated how many cells were concealing
HIV at various points of treatment, calculated how long it
would take this reservoir of infected cells to die, and came
up with an estimate of about 60 years.

Mortality Rising in Developing Countries Due to AIDS,
Environmental Limits
Reuters (04/12/99)

FDA Approves an AIDS Drug From Vertex
Wall Street Journal (04/ 19/99)

A new study from the concludes that HIV, falling
water stocks, and shrinking crop land are contributing to
rising mortality rates in the world's poorest nations. Lester
Brown, co-author of "Beyond Malthus, Nineteen
Dimensions of the Population Challenge, " notes that the
HIV epidemic is soaring out of control in some developing
nations, with infection rates as high as 20 percent to 25
percent in countries like Zambia and Botswana. Short of a
miracle, 20 percent to 25 percent of the adults in nations
with high HIV infection rates will die during the next seven
years, Brown forecast.

The U.S. Food and Drug Administration granted on
marketing authorization to Vertex Pharmaceuticals for
Agenerase, the fifth drug targeting HIV's protease enzyme
that has been approved for the treatment of AIDS. Vertex
developed the drug, which will be marketed by Glaxo
Wellcome, using technology licensed from Monsanto's G.D.
Searle unit. One advantage of Agenerase over other
approved protease drugs is that patients need take it only
twice a day, rather than three times a day; but users must
consume eight pills of Agenerase at each sitting, compared
to two to six when using the other drugs.
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Co111e On Out for a Walk!
The Outdoor/Wellness Group is continuing throughout the summer! The locations for the walks will be giiven to
you when you contact Denise Ferer, Case Manager, in TAP's York County Office by calling 985-8199. All those
interested can contact Denise directly!
This group has been put together so that you can be outside enjoying yourself and having fun while meetirng new
people! Trips are held one Saturday for each of the summer months from 11 :30 a.m. to approximately 2 p.m. Bring a
lunch, a pair of comfortable shoes and your good spirits! Transportation is provided, if needed.

The dates for the summerwalks are:
June 12
(rain date - June 19)
July 10
(rain date-July 17)
August 14
(rain date -Aug. 21)
SUPPORT GROUPS
FOR PEOPLE INFECTED
AND AFFECTED BY HIV/AIDS

MONDAYS
Time: 5:00 p.m. to 6:30 p.m.
Group: HIV and Substance Abuse
Location: Portland, The Meeting Room, Suite 632.
Contact Carolyn Curtis at TAP at 774-6877, or David
Gordon at Portland Public Health at 874-8784.

TUESDAYS
Time: 10:30a.m. to noon
Group: HIV Infected/Affected Drop-In Support Group
A meeting for people living with and affected by the virus.
Location: Portland, TAP. The Meeting Room, Suite 632.
Contact Susan Parr at TAP at 77 4-6877 for more info.

THURSDAYS

PROJECT

PROJECT

PROJECT

CLIENT SERVICES
MEDICAL ASSISTANT FUNDS

IMMEDIATE SEATING

An important reminder to clients:
There are funds available to TAP clients with financial need
for the following items: Routine Dental Care, Routine Eye
Care and Eyeglasses, Vitamin Supplements, NonPrescription Skin Care Products, and Non-Medicaid
Medication Co-pays.
There is a dollar limit to how much a client can receive in any
fiscal year. Contact your case manager for assistance.

For free tickets to area events as they become available,
sign up for "Immediate Seating." Call Daniel at TAP at 7746877 for more information.

WELLNESS AND YOU PROGRAM

A stress reduction and physical activity program
Time: 10:00 a.m. to 11 :30 a.m.
designed for people living with HIV/AIDS. In this program
Group: HIV Infected/Affected Drop-in Group
individuals can participate in a variety of supervised
A TAP-sponsored meeting for people
physical activity, education, and specialized stress
living with and affected by HIV/AIDS in southern Maine.
management segments. Contact Daniel at TAP at 77 4Location: Sanford, Unitarian Church, located at the comer of 6877 for more information.
Main St. (Rte. 1091 and Lebanon St. (Rte. 2021.
Contact Getty Payson at TAP at 985-8199 for more info.

THE MEETING ROOM
This room is used by TAP in Portland for support groups,
counseling and testing, and some client/case manager
meetings. Located in Suite 632, it provides more privacy for
people served by TAP.
Enter from the High Street side of the building.

I.V LEAGUE
Meetings of the 1.V. League support group are held on
Thursdays from 10:00 to 11 :30 a.m. at First Parish Church
at 425 Congress St. in Portland. (Use the right side entrance
and ring the bell.I This group is for IV Drug Users past and
present.
For more information, call Steve Farrell at 874-8775.

Time: 12 noon
Group: Open Lunch for TAP Clients/Staff
An informal luncheon gathering ofTAP staff and clients.
Location: Portland, TAP. Conference Room.
Contact Daniel Schnorbus atTAP at 774-6877 for info.

AIDS HOTLINES

HIV WEBSITES

TAP ON·LINE

Time: 5:30 p.m. to 7:00 p.m.
Group: People Uving with HIV/AIDS
A drop-in support group for anyone with HIV/AIDS.
Location: Portland, TAP. The Meeting Room, Suite 632.
Contact Susan Parr at TAP at 774-6877 for more info.

Questions about HIV/AIDS?
Call toll-free
National AIDS Hotline:
1-800-342-2437
Maine AIDSline:
1-800-851-2437

Check out these websites:
www.hivpositive.com
www.thebody.com
www.projinf.org
for info on HIV and AIDS.

Visit our new website at: www.aidsproject.org
To e-mail The AIDS Project,
send your message along to:
tap@aidsproject.org (Portland!
or tap2@mail.javanet.com (Kennebunk!

FOR YOUR INFORMATION

>>>>New Group<<<<
When: Day and Time to be announced
Group: Expressive Therapy
Explore your creativity through art, music, movement.
Location: Portland, The Meeting Room, Suite 632.
Contact Susan Parr at TAP at 774-6877 for more info.

~

For more information about programs
at The AIDS Project, call 774-6877.
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The Outdoor/Wellness Group is continuing throughout the summer! The locations for the walks will be given to
you when you contact Denise Ferer, Case Manager, in TAP's York County Office by calling 985-8199. All those
interested can contact Denise directly!
This group has been put together so that you can be outside enjoying yourself and having fun while meeting new
people! Trips are held one Saturday for each of the summer months from 11 :30 a.m. to approximately 2 p.m. Bring a
lunch, a pair of comfortable shoes and your good spirits! Transportation is provided, if needed.

The dates for the summerwalks are:
June 12
(rain date - June 19)
July 10
(rain date-July 17)
August 14
(rain date -Aug. 21)
SUPPORT GROUPS
FOR PEOPLE INFECTED
AND AFFECTED BY HIV/AIDS
MONDAYS
Time: 5:00 p.m. to 6:30 p.m.
Group: HIV and Substance Abuse
Location: Portland, The Meeting Room, Suite 632.
Contact Carolyn Curtis at TAP at 774-6877, or David
Gordon at Portland Public Health at 874-8784.

TUESDAYS
Time: 10:30 a.m. to noon
Group: HIV Infected/Affected Drop-In Support Group
A meeting for people living with and affected by the virus.
Location: Portland, TAP. The Meeting Room, Suite 632.
Contact Susan Parr at TAP at 774-6877 for more info.

THURSDAYS
Time: 10:00 a.m. to 11 :30 a.m.
Group: HIV Infected/Affected Drop-in Group
A TAP-sponsored meeting for people
living with and affected by HIV/AIDS in southern Maine.
Location: Sanford, Unitarian Church, located at the comer of
Main St. (Rte. 1091and Lebanon St. (Rte. 2021.
Contact Getty Payson at TAP at 985-8199 for more info.
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CLIENT SERVICES
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IMMEDIATE SEATING

An important reminder to clients:
There are funds available to TAP clients with financial need
for the following items: Routine Dental Care, Routine Eye
Care and Eyeglasses, Vitamin Supplements, NonPrescription Skin Care Products, and Non-Medicaid
Medication Co-pays.
There is a dollar limit to how much a client can receive in any
fiscal year. Contact your case manager for assistance.

For free tickets to area events as they become available,
sign up for "Immediate Seating." Call Daniel at TAP at 7746877 for more information.

WELLNESS AND YOU PROGRAM
A stress reduction and physical activity program
designed for people living with HIV/AIDS. In this program
individuals can participate in a variety of supervised
physical activity, education, and specialized stress
management segments. Contact Daniel at TAP at 7746877 for more information.

THE MEETING ROOM
This room is used by TAP in Portland for support groups,
counseling and testing, and some client/case manager
meetings. Located in Suite 632, it provides more privacy for
people served by TAP.
Enter from the High Street side of the building.

I.V LEAGUE
Meetings of the I.V. League support group are held on
Thursdays from 10:00 to 11 :30 a.m. at First Parish Church
at 425 Congress St. in Portland. (Use the right side entrance
and ring the b!!ll.t This group is for IV Drug Users past and
present.
For more information, call Steve Farrell at 874-8775.

Time: 12 noon
Group: Open Lunch for TAP Clients/Staff
An informal luncheon gathering ofTAP staff and clients.
Location: Portland, TAP. Conference Room.
Contact Daniel Schnorbus atTAP at 774-6877 for info.

AIDS HOTLINES

HIV WEBSITES

TAP ON-LINE

Time: 5:30 p.m. to 7:00 p.m.
Group: People Living with HIV/AIDS
A drop-in support group for anyone with HIV/AIDS.
Location: Portland, TAP. The Meeting Room, Suite 632.
Contact Susan Parr at TAP at 774-6877 for more info.

Questions about HIV/AIDS?
Call toll-free
National AIDS Hotline:
1-800-342-2437
Maine AIDSline:
1-800-851-2437

Check out these websites:
www.hivpositive.com
www.thebody.com
www.projinf.org
for info on HIV and AIDS.

Visit our new website at: www.aidsproject.org
To e-mail The AIDS Project,
send your message along to:
tap@aidsproject.org (Portland!
or tap2@mail.javanet.com (Kennebunk I

FOR YOUR INFORMATION

>>>>New Group<<<<
When: Day and Time to be announced
Group: Expressive Therapy
Explore your creativity through art, music, movement.
Location: Portland, The Meeting Room, Suite 632.
Contact Susan Parr at TAP at 774-6877 for more info.
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For more information about programs
at The AIDS Project, call 774-6877.
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